Latest Market Development News

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

Pepper Money Limited reported a record-breaking 2025 financial year, driven by strong growth in originations and assets under management, alongside enhanced ESG reporting and a significant acquisition proposal.

Acrow Limited reaffirms its first half FY26 revenue guidance with a 22% increase year-on-year, driven by robust demand in key Australian regions and strategic capital investments.

Deterra Royalties Limited has reported a record half-year net profit after tax of A$87.2 million, driven by strong revenue growth from its core Mining Area C royalty and successful divestment of non-core assets. The company also declared a higher fully franked interim dividend and advanced its Thacker Pass lithium project in Nevada.

Australian Vanadium Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information behind the market activity.

Tamawood Limited has reported a robust interim financial performance for the half year ended December 2025, showcasing significant growth in revenue, profit, and net tangible assets per share. The company’s reinstated dividend reinvestment plan and upcoming dividend review add to investor interest.

Impact Minerals has identified a promising standalone process to produce sulphate of potash and hydrochloric acid from lake clays in Western Australia, potentially reducing reliance on imports and addressing local industrial demand.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

New Frontier Minerals has completed the Stage 1 earn-in to secure an 85% interest in a pivotal tenement at its Harts Range Heavy Rare Earths Project, positioning the company strongly ahead of imminent assay results.

Pure One Corporation Limited has advanced its zero-emission mobility strategy with a new local vehicle assembly partnership, expanded US hydrogen market collaborations, and progressed the spin-out of its Australian gas assets via Eastern Gas IPO.

Resonance Health has reported record half-year revenue and strong progress in clinical trials, alongside promising new technology deployments set to enhance its global footprint.